LeonaBio, Inc. (NasdaqCM: LONA)
Health Care · Pharmaceuticals · US
$7.69
-3.52% today · +87.4% 1Y
LeonaBio, Inc. (NasdaqCM: LONA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $72.19M and employs 19 people.
Over the last twelve months the share price has gained 87.4%, trading between 3.53 and 14.21.
Tweenvest scores LeonaBio, Inc. across four factors: quality 26/100. Its strongest factor is quality.
LONA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $72.19M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -10.88
- Dividend yield
- —
- Beta (5Y)
- 2.04
- 52-week high
- $14.21
- 52-week low
- $3.53
- Avg volume (3M)
- —
- Shares outstanding
- 9.39M
- Employees
- 19
- Next earnings
- —
About LeonaBio, Inc.
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
- Founded
- 2011
- Listed since
- Sep 18, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.75 | +0.19% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.56 | +0.66% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.